abstract |
The use of a carbostyril derivative of formula (1) wherein the broken line represents a single or double bond, or a pharmaceutically acceptable salt or solvate thereof, for the production of a medicament for the treatment of associated central nervous system disorders with the 5-HT1A receptor subtype, selected from cognitive impairment caused by treatment-resistant schizophrenia, cognitive impairment caused by inveterate schizophrenia, or cognitive impairment caused by chronic schizophrenia. |